Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05726864 · ClinicalTrials.gov registry record · Phase 1
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
A Phase 1 study of Colorectal Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Elicio Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 158
- Enrollment target
- 20
- Study locations
NCT05726864 is a Phase 1 study of Colorectal Cancer and Pancreatic Ductal Adenocarcinoma that is active but no longer recruiting, run by Elicio Therapeutics. The registered enrollment target is 158 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT05726864, a Phase 1 study of Colorectal Cancer and Pancreatic Ductal Adenocarcinoma, is active but no longer recruiting, sponsored by Elicio Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 158 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[Amph-Peptides 7P\]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS. This study builds on the experience obtained with related product ELI-002 2P, which was studied in protocol ELI-002-001 under IND 26909.
Conditions Studied
Interventions
- DRUG ELI-002 7P
Study Locations (20)
California
- City of Hope - Duarte
- Cedars-Sinai Medical Center - Los Angeles
- University of California Los Angeles - Los Angeles
- University of California, Irvine - Orange
Florida
- University of Miami - Coral Gables
- University of Florida Health Cancer Center - Gainesville
- Mayo Clinic Comprehensive Cancer Center - Jacksonville
- Moffitt Cancer Center - Tampa
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Mayo Clinic Comprehensive Cancer Center - Phoenix
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
New York
- Northwell Health - Lake Success
- Memorial Sloan Kettering Cancer Center - New York
Colorado
- University of Colorado Hospital-Anschutz Cancer Pavillion - Aurora
Georgia
- Emory Winship Cancer Institute - Atlanta
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2023-04-14 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05726864
The ClinicalTrials.gov registry entry for NCT05726864 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Elicio Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which ELI-002 7P is the first listed.
NCT05726864 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05726864 about?
NCT05726864 is a clinical study titled "A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors". This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[Amph-Peptides 7P\]) as adjuvant treatment in subjects with solid tumors with mu...
What is the current status of trial NCT05726864?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 158 participants. The study started on 2023-04-14. Estimated completion is 2026-11.
What conditions does trial NCT05726864 study?
This clinical trial studies the following conditions: Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Kras G12C, Kras G12D, Kras G12A.
What interventions are being tested in trial NCT05726864?
The interventions under investigation include: ELI-002 7P (DRUG).
Who is sponsoring clinical trial NCT05726864?
This trial is sponsored by Elicio Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05726864 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.